With an increasingly promising roster of approved cell therapies still burdened by complex manufacturing, multiple companies ...
Dual-target CAR T cell therapy for recurrent glioblastoma (GBM), delivered directly into the cerebrospinal fluid (CSF), ...
Early results from a UCL- and UCLH-led clinical trial suggest that a type of CAR T-cell therapy—developed by Autolus ...
Researchers at the University of Maryland School of Medicine (UMSOM) have identified a target that may improve the response to CAR T-cell therapy, a treatment for patients with recurrent or ...
New findings presented at ASCO 2026 show that a CAR-T cell therapy called Breyanzi (lisocabtagene maraleucel) is producing ...
Researchers have identified a target that may improve the response of CAR T-cell therapy, a treatment for patients with ...
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that ...
Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the ...
June 2 () - Legend Biotech's experimental therapy showed early signs that its approach of generating disease-fighting cells within patients may work for a type of blood cancer, the company said on ...
I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...
AI-native platforms are reshaping stem cell research, making regenerative medicine faster, cheaper, and more precise.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results